Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer

Author:

Liu Longyang1ORCID,Hu Ke2,Zeng Zhaoyang3,Xu Caiqiu4,Lv Jin1,Lin Zhongqiu5,Wen Bin2

Affiliation:

1. Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 13 Shiliugang ST, Guangzhou 510315, China

2. Department of Gynecology, Guangdong Women and Children Hospital, Guangzhou 511442, China

3. Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 13 Shiliugang ST, Guangzhou 510315, China

4. Department of Obstetrics and Gynecology, Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, China

5. Department of Gynecology Oncology, the Memorial Hospital of Sun Yat-sen University, Guangzhou 510000, China

Abstract

Background: Ovarian Cancer (OC) remains the first leading cause of gynecologic malignancy. The survival rate from Serous Ovarian Cancer (SOC) is very low, and the present prognostic predictors of SOC are not very sensitive or specific. Objective: The present study aimed to investigate Microtubule-Actin Cross-Linking Factor 1 (MACF1) expression in SOC tissues (including paraffin-embedded and fresh tissues) and to assess its expression and significant value in patients with SOC. Methods: A total of 18 fresh SOC tissues and their paired paratumor tissues were performed with reverse-transcription quantitative PCR analysis to detect MACF1 mRNA expression. Moreover, 175 paraffin embedded SOC tissues and 41 paratumor tissues were assessed for MACF1 expression using immunohistochemistry. Results: The mRNA and protein expression of MACF1 were both higher in cancer tissues than that in paratumor tissues, and MACF1 high expression was associated with shorter Recurrence Free Survival (RFS) and Overall Survival (OS) in patients with SOC. Furthermore, multivariate regression analysis showed that high MACF1 expression was an independent poor survival predictor of patients with SOC. Conclusion: MACF1 is upregualted in SOC, and it may be used as a useful patent of prognostic biomarker in SOC.

Funder

Natural Science Foundation of Guangdong Province

Guangzhou Science and Information Bureau Item

Guangzhou Medical University

Southern Medical University

Guangdong Provincial Medical Research Fund

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3